EDITOX®

About Alcediag

Alcediag is an innovative diagnostics company pioneering the application of RNA editing biomarkers and AI to address critical unmet needs in mental health. Its core technology, the EDITECH® platform, analyzes epigenetic modifications in blood to develop tests like EDIT-B®, which aims to differentiate unipolar from bipolar depression. As a private company, Alcediag is positioned in the high-growth precision psychiatry market, leveraging a strong IP portfolio and KOL network to advance its commercial and diagnostic pipeline.

Therapeutic Areas